The company continues striving to take responsibility for inappropriate actions of some former employees and has invested significant resources over the last several years to establish an effective compliance program and build an organizational culture of high ethical standards. Intending to learn from past events, we also continue working with relevant authorities to resolve issues related to inappropriate actions taken by former employees.
Last week’s federal indictments of five
- focus on the actions of current employees and reinforce an organizational culture of high ethical standards;
- remain firmly committed to operating the business with a strong focus on the best interests of patients; and
- continue investing in innovating new treatment options for serious unmet patient needs.
We believe our actions over the last several years, including our significant investment in R&D programs, illustrate our commitment to these priorities and the company’s future.
|CONTACT:||Corporate Communications||Investor Relations|
|Joe McGrath||Jackie Marcus or Chris Hodges|
|INSYS Therapeutics||Alpha IR Group|